Earnings Feed
Start Free
ACADIA PHARMACEUTICALS INC·4

Jun 1, 6:00 PM ET

GAROFALO ELIZABETH A. 4

Research Summary

AI-generated summary

Updated

ACADIA (ACAD) Director Elizabeth Garofalo Exercises Options, Receives RSUs

What Happened
Elizabeth A. Garofalo, a director of ACADIA Pharmaceuticals (ACAD), recorded option exercise/conversion activity and receipt of restricted stock units (RSUs) in a Form 4 reporting transactions dated May 29, 2026. The filing shows an exercise/conversion involving 8,107 derivative shares and two awards totaling 25,315 RSUs (16,004 and 9,311). The exercise/conversion entries show an associated disposal of 8,107 shares at $0.00 (derivative), and the RSU awards are reported at $0.00 per share.

Key Details

  • Filing date: 2026-06-01; transaction date(s): 2026-05-29.
  • Derivative exercise/conversion (code M): 8,107 shares acquired; 8,107 shares disposed at $0.00.
  • Awards/grants (code A): 16,004 RSUs and 9,311 RSUs granted/recorded (total 25,315 RSUs). Reported price: $0.00.
  • Footnotes:
    • F1: Each RSU represents a contingent right to receive one share of common stock.
    • F2: The RSUs vested in full on May 29, 2026 (the issuer’s annual meeting).
    • F3: Stock options referenced will vest quarterly over one year following grant (final tranche earlier of one year post-grant or next annual meeting).
    • F4: The reporting person elected to defer receipt of the shares underlying the RSUs until the earliest of (i) the fifth anniversary of grant, (ii) 30 days after ceasing board service, or (iii) a change in control.
  • Shares owned after the transaction: not specified in the provided filing details.
  • No 10b5-1 plan or late-filing flag noted in the provided data.

Context

  • The M-code entries indicate exercise or conversion of derivative securities (e.g., option exercise). The simultaneous disposal at $0.00 likely reflects a non-cash settlement or internal withholding/settlement related to the exercise as reported (the filing does not provide additional detail).
  • The RSU awards vested on the annual meeting date, but the director has elected to defer receipt of the underlying shares under the plan’s deferral rules, so immediate share transfers to the director may be delayed.
  • These filings are informational about insider compensation and exercises; they do not, by themselves, indicate the director’s market view. Purchases are generally more directly interpreted as a bullish signal than awards or option exercises.